Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIFC1 | Q9BW19 | 8/20 | 0.58 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 4/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | ITGB7 | P26010 | 3/20 | 0.47 |
| ▸ | ECE1 | P42892 | 2/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4827800 | 1.00 | KIFC1 (0.58) | KIFC1GPR34CDK2ITGB1ITGA4 | |
| SCHEMBL4832021 | 0.96 | KIFC1 (0.55) | KIFC1GPR34CDK2ITGB1ITGA4 | |
| SCHEMBL4832015 | 0.96 | KIFC1 (0.55) | KIFC1GPR34CDK2ITGB1ITGA4 | |
| SCHEMBL4824086 | 0.95 | KIFC1 (0.59) | KIFC1GPR34CDK2ITGB1ITGA4 | |
| SCHEMBL3972237 | 0.95 | KIFC1 (0.59) | KIFC1GPR34CDK2ITGB1ITGA4 | |
| SCHEMBL4829768 | 0.94 | KIFC1 (0.51) | KIFC1GPR34CDK2ITGB1ITGA4 | |
| SCHEMBL4829763 | 0.94 | KIFC1 (0.51) | KIFC1GPR34CDK2ITGB1ITGA4 | |
| SCHEMBL4823623 | 0.92 | KIFC1 (0.49) | KIFC1GPR34CDK2ITGB1ITGA4 | |
| SCHEMBL4823679 | 0.92 | KIFC1 (0.49) | KIFC1GPR34CDK2ITGB1ITGA4 | |
| SCHEMBL4823683 | 0.92 | KIFC1 (0.49) | KIFC1GPR34CDK2ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| WO-2005014534-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | CYP2F1, CYP3A43, PNPO | KIFC1 2072/4885GPR34 2331/4885CDK2 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.